Consultants run all companies. Circassia expanded because they paid consultants to do an expansion map and the idiot consultants with their 1995 templates told them where to put territories. Many of us knew that many of the territories were bad locations likely to never show a profit. Now we reap the reward of more work with the consultants to fix the first errors. The territories that remain will likely be too large to do well so you will be in trouble from the start, especially the COPD/Tudorza side. It is likely they will nail one foot to the floor with the never-accurate target lists and demand you double sales, ride with your manager weekly and run around to get 4 sigs a day (which are rarely where the business is). You will get pipped quickly in all likelihood.
The bottom line is there is no secret-sauce to pour on our sales or magic plan to succeed where everyone else has failed on Tudorza. You have to take risks like head to head data or deep discounting to gain access. No one in pharma takes risks or uses new templates.
I think NIOX survives because it is unique and the data for it are getting better. Some other company will buy it or it can spin off on its own. Tudorza and the Pressair devices (Duaklir) probably die 60-90 days after launch when there is no growth curve. NIOX could survive but will still have to be remodeled.
